Search

Your search keyword '"Rastelli, Francesca"' showing total 135 results
Start Over Author "Rastelli, Francesca"
135 results on '"Rastelli, Francesca"'

1. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

2. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Author

Russano, Marco, Cortellini, Alessio, Giusti, Raffaele, Russo, Alessandro, Zoratto, Federica, Rastelli, Francesca, Gelibter, Alain, Chiari, Rita, Nigro, Olga, De Tursi, Michele, Bracarda, Sergio, Gori, Stefania, Grossi, Francesco, Bersanelli, Melissa, Calvetti, Lorenzo, Di Noia, Vincenzo, Scartozzi, Mario, Di Maio, Massimo, Bossi, Paolo, Falcone, Alfredo, Citarella, Fabrizio, Pantano, Francesco, Ficorella, Corrado, Filetti, Marco, Adamo, Vincenzo, Veltri, Enzo, Pergolesi, Federica, Occhipinti, Mario Alberto, Nicolardi, Linda, Tuzi, Alessandro, Di Marino, Pietro, Macrini, Serena, Inno, Alessandro, Ghidini, Michele, Buti, Sebastiano, Aprile, Giuseppe, Lai, Eleonora, Audisio, Marco, Intagliata, Salvatore, Marconcini, Riccardo, Brocco, Davide, Porzio, Giampiero, Piras, Marta, Rijavec, Erika, Simionato, Francesca, Natoli, Clara, Tiseo, Marcello, Vincenzi, Bruno, Tonini, Giuseppe, and Santini, Daniele

Published
2022
Full Text
View/download PDF

3. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Author

Cortellini, Alessio, Giusti, Raffaele, Filetti, Marco, Citarella, Fabrizio, Adamo, Vincenzo, Santini, Daniele, Buti, Sebastiano, Nigro, Olga, Cantini, Luca, Di Maio, Massimo, Aerts, Joachim G. J. V., Bria, Emilio, Bertolini, Federica, Ferrara, Miriam Grazia, Ghidini, Michele, Grossi, Francesco, Guida, Annalisa, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Antonuzzo, Lorenzo, Gelibter, Alain, Marchetti, Paolo, Chiari, Rita, Macerelli, Marianna, Rastelli, Francesca, Della Gravara, Luigi, Gori, Stefania, Tuzi, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Pecci, Federica, Zoratto, Federica, Ricciardi, Serena, Migliorino, Maria Rita, Passiglia, Francesco, Metro, Giulio, Spinelli, Gian Paolo, Banna, Giuseppe L., Friedlaender, Alex, Addeo, Alfredo, Ficorella, Corrado, Porzio, Giampiero, Tiseo, Marcello, Russano, Marco, Russo, Alessandro, and Pinato, David James

Published
2022
Full Text
View/download PDF

4. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

5. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Author

Cortellini, Alessio, Friedlaender, Alex, Banna, Giuseppe L., Porzio, Giampiero, Bersanelli, Melissa, Cappuzzo, Federico, Aerts, Joachim G.J.V., Giusti, Raffaele, Bria, Emilio, Cortinovis, Diego, Grossi, Francesco, Migliorino, Maria R., Galetta, Domenico, Passiglia, Francesco, Berardi, Rossana, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Tuzi, Alessandro, Gelibter, Alain, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Santoni, Matteo, Tudini, Marianna, Ghidini, Michele, Filetti, Marco, Catino, Annamaria, Pizzutilo, Pamela, Sala, Luca, Occhipinti, Mario Alberto, Citarella, Fabrizio, Russano, Marco, Torniai, Mariangela, Cantini, Luca, Follador, Alessandro, Sforza, Vincenzo, Nigro, Olga, Ferrara, Miriam G., D’Argento, Ettore, Leonetti, Alessandro, Pettoruti, Linda, Antonuzzo, Lorenzo, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Baldessari, Cinzia, Bertolini, Federica, Della Gravara, Luigi, Dal Bello, Maria Giovanna, Belderbos, Robert A., De Filippis, Marco, Cecchi, Cristina, Ricciardi, Serena, Donisi, Clelia, De Toma, Alessandro, Proto, Claudia, Addeo, Alfredo, Cantale, Ornella, Ricciuti, Biagio, Genova, Carlo, Morabito, Alessandro, Santini, Daniele, Ficorella, Corrado, and Cannita, Katia

Published
2020
Full Text
View/download PDF

6. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Author

Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, and Cortellini, Alessio

Published
2021
Full Text
View/download PDF

7. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Author

Cortellini, Alessio, Tiseo, Marcello, Banna, Giuseppe L., Cappuzzo, Federico, Aerts, Joachim G. J. V., Barbieri, Fausto, Giusti, Raffaele, Bria, Emilio, Cortinovis, Diego, Grossi, Francesco, Migliorino, Maria R., Galetta, Domenico, Passiglia, Francesco, Santini, Daniele, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Tuzi, Alessandro, Gelibter, Alain, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Gori, Stefania, De Tursi, Michele, Mansueto, Giovanni, Zoratto, Federica, Santoni, Matteo, Tudini, Marianna, Rijavec, Erika, Filetti, Marco, Catino, Annamaria, Pizzutilo, Pamela, Sala, Luca, Citarella, Fabrizio, Marco, Russano, Torniai, Mariangela, Cantini, Luca, Targato, Giada, Sforza, Vincenzo, Nigro, Olga, Ferrara, Miriam G., D’Argento, Ettore, Buti, Sebastiano, Bordi, Paola, Antonuzzo, Lorenzo, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Baldessari, Cinzia, Della Gravara, Luigi, Dal Bello, Maria Giovanna, Belderbos, Robert A., Bironzo, Paolo, Carnio, Simona, Ricciardi, Serena, Grieco, Alessio, De Toma, Alessandro, Proto, Claudia, Friedlaender, Alex, Cantale, Ornella, Ricciuti, Biagio, Addeo, Alfredo, Metro, Giulio, Ficorella, Corrado, and Porzio, Giampiero

Published
2020
Full Text
View/download PDF

8. Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

9. Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK

Author

Tavabie, Oliver D, primary, Abeysekera, Kushala WM, additional, Brennan, Paul N, additional, Marjot, Thomas, additional, Kronsten, Victoria T, additional, Li, Wenhao, additional, Nayagam, Jeremy S, additional, Dhaliwal, Amritpal, additional, Hardy, Tim, additional, Maurice, James B, additional, Zakeri, Nekisa, additional, Abbas, Nadir, additional, Abbasi, Abdullah, additional, Abbott, Jane, additional, Abdul, Rahman, additional, Abdulaziz, Mohamed, additional, Abduljabbar, Duaa, additional, Adamson, Robbie, additional, Adebayo, Danielle, additional, Adhikarla, Aditya Kumar, additional, Adler, Maciej, additional, Afifi, Mostafa, additional, Ahmad, Salman, additional, Ahmed, Shayan, additional, Aithal, Guruprasad, additional, Akram, Ali, additional, Al Radhi, Balqees, additional, Al-Talib, Ismaeel, additional, Alele, Jolomi, additional, Ali, Alaa Mohammed, additional, Almusai, Safa, additional, Appleby, Victoria, additional, Asmat, Huma, additional, Astbury, Sarah, additional, Atkinson, Ali, additional, Badrulhisham, Fakhirah, additional, Balachandrakumar, Vinay K, additional, Ball, Alexandra, additional, Banfa, Moses, additional, Barn, Jeevan, additional, Begum, Shahnaz, additional, Belfield, Katherine, additional, Bendall, Oliver, additional, Bennett, Kris, additional, Bernal, William, additional, Bhandari, Rajan, additional, Bhatti, Prashan, additional, Bradley, Meg, additional, Brown, Edward, additional, Bryce, Kathleen, additional, Buchanan, Ryan, additional, Burke, Laura, additional, Campbell, Roisin, additional, Cargill, Tamsin, additional, Carroll, Geraldine, additional, Cartledge, James, additional, Chatterjee, Devnandan, additional, Chaundry, Rayan, additional, Choudhry, Zeshan, additional, Clare, Kathleen, additional, Cobbold, Jeremy, additional, Coburn, Robert, additional, Cook, Charlotte, additional, Corvan, Fintan, additional, Cox, Rebecca, additional, Craig, Darren, additional, Creamer, John, additional, Curran, Christopher, additional, De Silva, Shanika, additional, Dean, Laurence, additional, Dillon, Jayne, additional, Dillon, John, additional, Dunn, Rebecca, additional, Eckersley, Robert, additional, Eike, Gidveig, additional, Elagib, Amul, additional, Elkholi, Ayman, additional, Elshaarawy, Omar, additional, Faloon, Sarah, additional, Fan, Francis, additional, Fazili, Mohammad, additional, Fernandes, Denzil, additional, Fox, James, additional, Foxton, Matthew, additional, Gaba, Waqas, additional, Gaikwad, Girish, additional, Gairola, Abishek, additional, Galanakis, Vasileios, additional, Gallaher, Charles, additional, Gautam, Nisham, additional, Germain, Lewis, additional, Giles, Ben, additional, Gill, Ceri, additional, Glover, Ben, additional, Glover, John, additional, Gomez, David, additional, Gomez, Michael, additional, Gordon, Victoria, additional, Gormley, Sarah, additional, Goulder, John, additional, Goyal, Simran, additional, Greenham, Olivia, additional, Guthrie, Sarah, additional, Hackett, Richard, additional, Haddadin, Yazan, additional, Hadjinicolaou, Andreas, additional, Hall, Jonathan, additional, Hamza, Mohammed, additional, Haque, Tasnuma, additional, Harris, Rebecca, additional, Hart, Catherine, additional, Hasan, Sundas, additional, Hasnain Nadir, Syed Mujtaba, additional, Hassall, James, additional, Hawker-Bond, George, additional, Hawkyard, Jake, additional, Healey, Scott, additional, Hogan, Brian, additional, Hornby, Catherine, additional, Humayun, MD, additional, Hutchison, John, additional, Iftikhar, Zahra, additional, Ismail, Asem, additional, James, Joel, additional, Jones, Rebecca, additional, Jopson, Laura, additional, Juthani, Dipal, additional, Kaina, Philippa, additional, Karim, Aadil, additional, Karim, Syed Misbah, additional, Kashyap, Vaishnavi, additional, Kassab, Mohamed, additional, Katarey, Dev, additional, Kenny, Lee, additional, Kerry, Georgina, additional, Khan, Adnan, additional, Khan, Ayesha, additional, Khan, Azab, additional, Khan, Muhammad Taha, additional, Khan, Tahir, additional, Khatib, Aseil, additional, Khattak, Mohammad Fawad, additional, King, Ji Jade, additional, Kooner, Emily, additional, Korani, Mohammed, additional, Kotha, Sreelakshmi, additional, Lam, Wai Liam, additional, Lateef, Mohammed, additional, Leighton, Jess, additional, Leith, Damien, additional, Liaros, Angela, additional, Liu Yin, James, additional, Lourenco, Floyd, additional, Lyles, Annabel, additional, Macken, Lucia, additional, Magee, Ciaran, additional, Maggs, Daniel, additional, Mahalingam, Aarani, additional, Mahenthiran, Midusa, additional, Mahmood, Rizwan, additional, Mandour, Mandour Omer, additional, Manocha, Namita, additional, Mansour, Dina, additional, Marks, Daniella, additional, Martin, Ciara, additional, Martin, Harry, additional, Martin, Iana, additional, Martin, Katherine, additional, Maruthan, Sachan, additional, Masin, Rhys, additional, Mason, Denise, additional, Matthews, Charmaine, additional, Mavrou, Athina, additional, Maxan, Ema, additional, Maxfield, Dominic, additional, McAvoy, Emma, additional, McCaughan, Hannah, additional, McColl, Kirsty, additional, McCorry, Roger, additional, McDonald, Stewart, additional, McDowell, Hannah, additional, McGoran, John, additional, McIlwane, Stewart, additional, McPherson, Stuart, additional, Meakin, Olivia, additional, Mebarek, Leila, additional, Merrill, Hannah, additional, Michail, Stephanie, additional, Modarres, Pedram, additional, Mohamedali, Alaa, additional, Mohammed, Yaser, additional, Mohammed, Zakiuddin, additional, Mohan, Jaiganesh, additional, Monnier, Chloe, additional, Moran, Eilis, additional, Moroni, Francesca, additional, Morrison, Gary, additional, Msaddi, Anas, additional, Mutar, Sarah, additional, Nahed, Ismail, additional, Navaratnam, Janardhan, additional, Neto-Pereira, Luis, additional, Ng, Jennifer, additional, Nwoguh, Chinonso, additional, O'Kane, Rebecca, additional, Omar, Sohail, additional, Ososanya, Abosede, additional, Parambil, Jessiya Veliyankodan, additional, Patel, Jay, additional, Pericleous, Marinos, additional, Pervais, Zeshan, additional, Phoolchund, Anju, additional, Pietrzycki, Julian, additional, Pillay, Lushen, additional, Pohl, Keith, additional, Prabhu, Kiran, additional, Putri, Yesita Rizky F., additional, Qazi, Umang, additional, Rafique, Khizar Khalid, additional, Raghuraman, Arun, additional, Raman, Krithivasan, additional, Ranade, Vaishali, additional, Rastelli, Francesca, additional, Ratcliffe, Elizabeth, additional, Rattehalli, Deepa, additional, Raza, Tufail, additional, Razak, Amir, additional, Read, George, additional, Robins, Anne, additional, Rowe, Ian, additional, Rushbrook, Simon, additional, Salama, Mohamed, additional, Saravan, Ramasamy, additional, Sarkar, Srishti, additional, Saunsbury, Emma, additional, Scott, Jennifer, additional, Serna, Solange, additional, Shahzad, Hassnain, additional, Shamsaldeen, Mohammed, additional, Sharip, Mohammed, additional, Shearer, Jessica, additional, Sheikh, Adam, additional, Sheiybani, Giovanna, additional, Sherwin, Michelle, additional, Sheth, Abhishek, additional, Shintre, Nidhi, additional, Singhal, Saket, additional, Sinha, Rohit, additional, Sinharay, Ricky, additional, Smith, Gloria, additional, Smith, Ria, additional, Snowdon, Victoria, additional, Spicer, Joanne, additional, Spoor, Johannes, additional, Sreenivasan, Shiva, additional, Srinivasa, Amar, additional, Srivastava, Ankur, additional, St. Aimee, Louise, additional, Stagg, Georgia, additional, Stanley, Jatinder, additional, Stevenson, Jason, additional, Stokes, Daniel, additional, Stroud, Robert, additional, Subhani, Mohsan, additional, Suliman, Hiba, additional, Sultana, Marium, additional, Summers, Nikki, additional, Sutherland, Chloe, additional, Swann, Rachael, additional, Sykes, Lynne, additional, Taha, Mostafa, additional, Tan, Kwei Eng, additional, Tariq, Zohaib, additional, Tay, Joshua Jun Ming, additional, Taylor, Alison, additional, Thakor, Amit, additional, Tsang, James, additional, Turner, Lucy, additional, Tyler, Zaccharie, additional, Unitt, Esther, additional, Volcek, Edward, additional, Watson, Iona, additional, Watters, Chris, additional, Wells, Gemma, additional, White, Helen, additional, Widlak, Monika, additional, Williams, Matthew, additional, Wischhusen, Jack, additional, Woodland, Hazel, additional, Wren, Louise, additional, Xyda, Souzana, additional, Yeh, Julian, additional, Young, Alison, additional, and Yuan, Jack Shie Jie, additional

Published
2023
Full Text
View/download PDF

10. Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy

Author

Giampieri, Riccardo, primary, Baleani, Maria Giuditta, additional, Bittoni, Alessandro, additional, Rastelli, Francesca, additional, Catalano, Vincenzo, additional, Del Prete, Michela, additional, Chiorrini, Silvia, additional, Pinterpe, Giada, additional, Graziano, Francesco, additional, Giorgi, Francesca Chiara, additional, Bisonni, Renato, additional, Silva, Rosarita, additional, Alessandroni, Paolo, additional, Mencarini, Lara, additional, and Berardi, Rossana, additional

Published
2023
Full Text
View/download PDF

11. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, primary, Cleary, Siobhan, primary, Buti, Sebastiano, primary, Bersanelli, Melissa, primary, Bordi, Paola, primary, Tonini, Giuseppe, primary, Vincenzi, Bruno, primary, Tucci, Marco, primary, Russo, Alessandro, primary, Pantano, Francesco, primary, Russano, Marco, primary, Stucci, Luigia Stefania, primary, Sergi, Maria Chiara, primary, Falconi, Martina, primary, Zarzana, Maria Antonietta, primary, Santini, Daniele, primary, Spagnolo, Francesco, primary, Tanda, Enrica T., primary, Rastelli, Francesca, primary, Giorgi, Francesca Chiara, primary, Pergolesi, Federica, primary, Giusti, Raffaele, primary, Filetti, Marco, primary, Lo Bianco, Francesca, primary, Marchetti, Paolo, primary, Botticelli, Andrea, primary, Gelibter, Alain, primary, Siringo, Marco, primary, Ferrari, Marco, primary, Marconcini, Riccardo, primary, Vitale, Maria Giuseppa, primary, Nicolardi, Linda, primary, Chiari, Rita, primary, Ghidini, Michele, primary, Nigro, Olga, primary, Grossi, Francesco, primary, De Tursi, Michele, primary, Di Marino, Pietro, primary, Queirolo, Paola, primary, Bracarda, Sergio, primary, Macrini, Serena, primary, Inno, Alessandro, primary, Zoratto, Federica, primary, Veltri, Enzo, primary, Spoto, Chiara, primary, Vitale, Maria Grazia, primary, Cannita, Katia, primary, Gennari, Alessandra, primary, Morganstein, Daniel L., primary, Mallardo, Domenico, primary, Nibid, Lorenzo, primary, Sabarese, Giovanna, primary, Brunetti, Leonardo, primary, Perrone, Giuseppe, primary, Ascierto, Paolo A., primary, Ficorella, Corrado, primary, and Pinato, David J., primary

Published
2023
Full Text
View/download PDF

13. Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

Author

Cortellini, Alessio, primary, D'Alessio, Antonio, additional, Cleary, Siobhan, additional, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Bordi, Paola, additional, Tonini, Giuseppe, additional, Vincenzi, Bruno, additional, Tucci, Marco, additional, Russo, Alessandro, additional, Pantano, Francesco, additional, Russano, Marco, additional, Stucci, Luigia Stefania, additional, Sergi, Maria Chiara, additional, Falconi, Martina, additional, Zarzana, Maria Antonietta., additional, Santini, Daniele, additional, Spagnolo, Francesco, additional, Tanda, Enrica T., additional, Rastelli, Francesca, additional, Giorgi, Francesca Chiara., additional, Pergolesi, Federica, additional, Giusti, Raffaele, additional, Filetti, Marco, additional, Lo Bianco, Francesca, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Gelibter, Alain, additional, Siringo, Marco, additional, Ferrari, Marco, additional, Marconcini, Riccardo, additional, Vitale, Maria Giuseppa., additional, Nicolardi, Linda, additional, Chiari, Rita, additional, Ghidini, Michele, additional, Nigro, Olga, additional, Grossi, Francesco, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Queirolo, Paola, additional, Bracarda, Sergio, additional, Macrini, Serena, additional, Inno, Alessandro, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Spoto, Chiara, additional, Vitale, Maria Grazia., additional, Cannita, Katia, additional, Gennari, Alessandra, additional, Morganstein, Daniel L., additional, Mallardo, Domenico, additional, Nibid, Lorenzo, additional, Sabarese, Giovanna, additional, Brunetti, Leonardo, additional, Perrone, Giuseppe, additional, Ascierto, Paolo A., additional, Ficorella, Corrado, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

14. Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis

Author

Tavabie, Oliver D., Abbott, Jane, Abeysekera, Kushala WM., Balachandrakumar, Vinay K., Bennett, Kris, Brennan, Paul, Buchanan, Ryan, Dhaliwal, Amritpal, Galanakis, Vasileios, Hardy, Tim, Harris, Rebecca, Kronsten, Victoria T., Leighton, Jess, Li, Wenhao, Yin, James Liu, Macken, Lucia, Marjot, Thomas, Maurice, James B., McDowell, Hannah, Navaratnam, Janardhan, Pohl, Keith, Nayagam, Jeremy S., Saunsbury, Emma, Scott, Jennifer, Sheth, Abhishek, Sinharay, Ricky, Sheiybani, Giovanna, Subhani, Mohsan, Turner, Lucy, White, Helen, Zakeri, Nekisa, Cook, Charlotte, Abbas, Nadir, Abbasi, Abdullah, Abdul, Rahman, Abdulaziz, Mohamed, Abduljabbar, Duaa, Adamson, Robbie, Adebayo, Danielle, Adhikarla, Aditya Kumar, Adler, Maciej, Ahmad, Salman, Ahmed, Shayan, Afifi, Mostafa, Akram, Ali, Al Radhi, Balqees, Al-Talib, Ismaeel, Alele, Jolomi, Ali, Alaa Mohammed, Almusai, Safa, Appleby, Victoria, Asmat, Huma, Astbury, Sarah, Atkinson, Ali, Badrulhisham, Fakhirah, Ball, Alexandra, Banfa, Moses, Barn, Jeevan, Begum, Shahnaz, Belfield, Katherine, Bendall, Oliver, Bhandari, Rajan, Bhatti, Prashan, Bradley, Meg, Brown, Edward, Bryce, Kathleen, Burke, Laura, Campbell, Roisin, Cargill, Tamsin, Carroll, Geraldine, Cartledge, James, Chatterjee, Devnandan, Chaundry, Rayan, Choudhry, Zeshan, Clare, Kathleen, Cobbold, Jeremy, Coburn, Robert, Corvan, Fintan, Cox, Rebecca, Craig, Darren, Creamer, John, Curran, Christopher, De Silva, Shanika, Dean, Laurence, Dillon, Jayne, Dunn, Rebecca, Eckersley, Robert, Eike, Gidveig, Elagib, Amul, Elkholi, Ayman, Elshaarawy, Omar, Faloon, Sarah, Fan, Francis, Fazili, Mohammad, Fernandes, Denzil, Fox, James, Foxton, Matthew, Gaba, Waqas, Gaikwad, Girish, Gairola, Abishek, Gallaher, Charles, Gautam, Nisham, Germain, Lewis, Giles, Ben, Gill, Ceri, Glover, Ben, Glover, John, Gomez, David, Gomez, Michael, Gordon, Victoria, Gormley, Sarah, Goulder, John, Goyal, Simran, Greenham, Olivia, Guthrie, Sarah, Hackett, Richard, Haddadin, Yazan, Hadjinicolaou, Andreas, Hall, Jonathan, Haque, Tasnuma, Hart, Catherine, Hasnain Nadir, Syed Mujtaba, Hassall, James, Hasan, Sundas, Hawker-Bond, George, Hawkyard, Jake, Healey, Scott, Hornby, Catherine, Hamza, Mohammed, Humayun, M.D., Hutchison, John, Iftikhar, Zahra, Ismail, Asem, James, Joel, Jopson, Laura, Juthani, Dipal, Kaina, Philippa, Karim, Aadil, Karim, Syed Misbah, Kashyap, Vaishnavi, Kassab, Mohamed, Katarey, Dev, Kenny, Lee, Kerry, Georgina, Khan, Adnan, Khan, Ayesha, Khan, Azab, Khan, Muhammad Taha, Khan, Tahir, Khatib, Aseil, Khattak, Mohammad Fawad, King, Ji Jade, Korani, Mohammed, Kotha, Sreelakshmi, Kooner, Emily, Lam, Wai Liam, Lateef, Mohammed, Leith, Damien, Liaros, Angela, Lourenco, Floyd, Lyles, Annabel, Mahenthiran, Midusa, Magee, Ciaran, Maggs, Daniel, Mahalingam, Aarani, Mahmood, Rizwan, Mandour, Mandour Omer, Manocha, Namita, Mansour, Dina, Marks, Daniella, Martin, Ciara, Martin, Harry, Martin, Iana, Martin, Katherine, Maruthan, Sachan, Masin, Rhys, Mason, Denise, Matthews, Charmaine, Mavrou, Athina, Maxan, Ema, Maxfield, Dominic, McAvoy, Emma, McColl, Kirsty, McCaughan, Hannah, McCorry, Roger, McGoran, John, McDonald, Stewart, McIlwane, Stewart, Meakin, Olivia, Mebarek, Leila, Merrill, Hannah, Michail, Stephanie, Modarres, Pedram, Mohamedali, Alaa, Mohammed, Yaser, Mohammed, Zakiuddin, Mohan, Jaiganesh, Monnier, Chloe, Moran, Eilis, Morrison, Gary, Moroni, Francesca, Msaddi, Anas, Mutar, Sarah, Neto-Pereira, Luis, Nahed, Ismail, Ng, Jennifer, Nwoguh, Chinonso, O’Kane, Rebecca, Omar, Sohail, Ososanya, Abosede, Parambil, Jessiya Veliyankodan, Patel, Jay, Pericleous, Marinos, Pervais, Zeshan, Phoolchund, Anju, Pietrzycki, Julian, Pillay, Lushen, Prabhu, Kiran, Putri, Yesita Rizky F., Qazi, Umang, Rafique, Khizar Khalid, Raman, Krithivasan, Ranade, Vaishali, Rastelli, Francesca, Ratcliffe, Elizabeth, Rattehalli, Deepa, Raza, Tufail, Razak, Amir, Raghuraman, Arun, Read, George, Robins, Anne, Rushbrook, Simon, Salama, Mohamed, St. Aimee, Louise, Saravan, Ramasamy, Sarkar, Srishti, Serna, Solange, Shahzad, Hassnain, Shamsaldeen, Mohammed, Sharip, Mohammed, Shearer, Jessica, Sheikh, Adam, Sherwin, Michelle, Shintre, Nidhi, Singhal, Saket, Sinha, Rohit, Smith, Gloria, Smith, Ria, Spicer, Joanne, Spoor, Johannes, Sreenivasan, Shiva, Srinivasa, Amar, Srivastava, Ankur, Stagg, Georgia, Stanley, Jatinder, Stevenson, Jason, Stokes, Daniel, Stroud, Robert, Suliman, Hiba, Sultana, Marium, Summers, Nikki, Sutherland, Chloe, Swann, Rachael, Sykes, Lynne, Taha, Mostafa, Tan, Kwei Eng, Tariq, Zohaib, Ming Tay, Joshua Jun, Taylor, Alison, Thakor, Amit, Tsang, James, Tyler, Zaccharie, Unitt, Esther, Volcek, Edward, Wischhusen, Jack, Watson, Iona, Watters, Chris, Wells, Gemma, Widlak, Monika, Williams, Matthew, Woodland, Hazel, Wren, Louise, Xyda, Souzana, Yeh, Julian, Young, Alison, Jie Yuan, Jack Shie, Aithal, Guruprasad, Bernal, William, Dillon, John, Hogan, Brian, McPherson, Stuart, Jones, Rebecca, Rowe, Ian, and Snowdon, Victoria

Published
2023
Full Text
View/download PDF

15. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Author

Cortellini, Alessio, Vitale, Maria G., De Galitiis, Federica, Di Pietro, Francesca R., Berardi, Rossana, Torniai, Mariangela, De Tursi, Michele, Grassadonia, Antonino, Di Marino, Pietro, Santini, Daniele, Zeppola, Tea, Anesi, Cecilia, Gelibter, Alain, Occhipinti, Mario Alberto, Botticelli, Andrea, Marchetti, Paolo, Rastelli, Francesca, Pergolesi, Federica, Tudini, Marianna, Silva, Rosa Rita, Mallardo, Domenico, Vanella, Vito, Ficorella, Corrado, Porzio, Giampiero, and Ascierto, Paolo A.

Published
2019
Full Text
View/download PDF

16. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Author

Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario Alberto, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado, and Natoli, Clara

Published
2019
Full Text
View/download PDF

18. Tool-use Extends Peripersonal Space Boundaries in Schizophrenic Patients

Author

Ferroni, Francesca, primary, Ardizzi, Martina, additional, Magnani, Francesca, additional, Ferri, Francesca, additional, Langiulli, Nunzio, additional, Rastelli, Francesca, additional, Lucarini, Valeria, additional, Giustozzi, Francesca, additional, Volpe, Roberto, additional, Marchesi, Carlo, additional, Tonna, Matteo, additional, and Gallese, Vittorio, additional

Published
2022
Full Text
View/download PDF

19. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

Author

Banna, Giuseppe L., Tiseo, Marcello, Cortinovis, Diego L., Facchinetti, Francesco, Aerts, Joachim G.J.V., Baldessari, Cinzia, Giusti, Raffaele, Bria, Emilio, Grossi, Francesco, Berardi, Rossana, Morabito, Alessandro, Catino, Annamaria, Genova, Carlo, Mazzoni, Francesca, Gelibter, Alain, Rastelli, Francesca, Macerelli, Marianna, Chiari, Rita, Gori, Stefania, Mansueto, Giovanni, Citarella, Fabrizio, Cantini, Luca, Rijavec, Erika, Bertolini, Federica, Cappuzzo, Federico, De Toma, Alessandro, Friedlaender, Alex, Metro, Giulio, Pensieri, Maria Vittoria, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Cortellini, Alessio, Addeo, Alfredo, Banna, Giuseppe L., Tiseo, Marcello, Cortinovis, Diego L., Facchinetti, Francesco, Aerts, Joachim G.J.V., Baldessari, Cinzia, Giusti, Raffaele, Bria, Emilio, Grossi, Francesco, Berardi, Rossana, Morabito, Alessandro, Catino, Annamaria, Genova, Carlo, Mazzoni, Francesca, Gelibter, Alain, Rastelli, Francesca, Macerelli, Marianna, Chiari, Rita, Gori, Stefania, Mansueto, Giovanni, Citarella, Fabrizio, Cantini, Luca, Rijavec, Erika, Bertolini, Federica, Cappuzzo, Federico, De Toma, Alessandro, Friedlaender, Alex, Metro, Giulio, Pensieri, Maria Vittoria, Porzio, Giampiero, Ficorella, Corrado, Pinato, David J., Cortellini, Alessio, and Addeo, Alfredo

Abstract

Background: Patients with programmed cell death-ligand 1 (PD-L1) ≥50% metastatic non-small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first-line immunotherapy have heterogeneous clinical assessment and outcomes. Methods: To explore the role of immune-inflammatory surrogates by the validated lung immuno-oncology prognostic score (LIPS) score, including the neutrophil-to-lymphocyte ratio (NLR) and the pretreatment use of steroids, alongside other prognostic variables. A retrospective analysis of 128 patients with PS2 and PD-L1 ≥50% mNSCLC treated between April 2018 and September 2019 with first-line pembrolizumab in a real-world setting was performed. Results: With a median follow-up of 15.3 months, the 1-year overall survival (OS) and median progression-free survival (PFS) were 32.3% (95% CI: 30.9–33.9) and 3.3 months (95% CI: 1.8–4.7), respectively. The NLR, lactate dehydrogenase (LDH) and pretreatment steroids results were the only significant prognostic factors on the univariate analysis and independent prognostic factors by the multivariate analysis on both OS and PFS. The LIPS score, including the NLR and pretreatment steroids, identified 29 (23%) favourable-risk patients, with 0 factors, 1-year OS of 67.6% and median PFS of 8.2 months; 57 (45%) intermediate-risk patients, with 1 factor, 1-year OS 32.1% and median PFS 2.7 months; 42 (33%) poor-risk patients, with both factors, 1-year OS of 10.7% and median PFS of 1.2 months. Conclusions: The assessment of pre-existing imbalance of the host immune response by combined blood and clinical immune-inflammatory markers may represent a way to unravel the heterogeneous outcome and assessment of patients with mNSCLC and poor PS in the immune-oncology setting.

Published
2022

20. Biallelic variants in TAMM41 are associated with low muscle cardiolipin levels, leading to neonatal mitochondrial disease

Author

Thompson, Kyle, primary, Bianchi, Lucas, additional, Rastelli, Francesca, additional, Piron-Prunier, Florence, additional, Ayciriex, Sophie, additional, Besmond, Claude, additional, Hubert, Laurence, additional, Barth, Magalie, additional, Barbosa, Inês A., additional, Deshpande, Charu, additional, Chitre, Manali, additional, Mehta, Sarju G., additional, Wever, Eric J.M., additional, Marcorelles, Pascale, additional, Donkervoort, Sandra, additional, Saade, Dimah, additional, Bönnemann, Carsten G., additional, Chao, Katherine R., additional, Cai, Chunyu, additional, Iannaccone, Susan T., additional, Dean, Andrew F., additional, McFarland, Robert, additional, Vaz, Frédéric M., additional, Delahodde, Agnès, additional, Taylor, Robert W., additional, and Rötig, Agnès, additional

Published
2022
Full Text
View/download PDF

21. Additional file 1 of High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Author

Cortellini, Alessio, Giusti, Raffaele, Filetti, Marco, Citarella, Fabrizio, Adamo, Vincenzo, Santini, Daniele, Buti, Sebastiano, Nigro, Olga, Cantini, Luca, Di Maio, Massimo, Aerts, Joachim G. J. V., Bria, Emilio, Bertolini, Federica, Ferrara, Miriam Grazia, Ghidini, Michele, Grossi, Francesco, Guida, Annalisa, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Antonuzzo, Lorenzo, Gelibter, Alain, Marchetti, Paolo, Chiari, Rita, Macerelli, Marianna, Rastelli, Francesca, Della Gravara, Luigi, Gori, Stefania, Tuzi, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Pecci, Federica, Zoratto, Federica, Ricciardi, Serena, Migliorino, Maria Rita, Passiglia, Francesco, Metro, Giulio, Spinelli, Gian Paolo, Banna, Giuseppe L., Friedlaender, Alex, Addeo, Alfredo, Ficorella, Corrado, Porzio, Giampiero, Tiseo, Marcello, Russano, Marco, Russo, Alessandro, and Pinato, David James

Abstract

Additional file 1. Supplementary materials.

Published
2022
Full Text
View/download PDF

22. Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

Author

Banna, Giuseppe L., primary, Tiseo, Marcello, additional, Cortinovis, Diego L., additional, Facchinetti, Francesco, additional, Aerts, Joachim G. J. V., additional, Baldessari, Cinzia, additional, Giusti, Raffaele, additional, Bria, Emilio, additional, Grossi, Francesco, additional, Berardi, Rossana, additional, Morabito, Alessandro, additional, Catino, Annamaria, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Gelibter, Alain, additional, Rastelli, Francesca, additional, Macerelli, Marianna, additional, Chiari, Rita, additional, Gori, Stefania, additional, Mansueto, Giovanni, additional, Citarella, Fabrizio, additional, Cantini, Luca, additional, Rijavec, Erika, additional, Bertolini, Federica, additional, Cappuzzo, Federico, additional, De Toma, Alessandro, additional, Friedlaender, Alex, additional, Metro, Giulio, additional, Pensieri, Maria Vittoria, additional, Porzio, Giampiero, additional, Ficorella, Corrado, additional, Pinato, David J., additional, Cortellini, Alessio, additional, and Addeo, Alfredo, additional

Published
2021
Full Text
View/download PDF

23. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Author

Russano, Marco, primary, Cortellini, Alessio, additional, Giusti, Raffaele, additional, Russo, Alessandro, additional, Zoratto, Federica, additional, Rastelli, Francesca, additional, Gelibter, Alain, additional, Chiari, Rita, additional, Nigro, Olga, additional, De Tursi, Michele, additional, Bracarda, Sergio, additional, Gori, Stefania, additional, Grossi, Francesco, additional, Bersanelli, Melissa, additional, Calvetti, Lorenzo, additional, Di Noia, Vincenzo, additional, Scartozzi, Mario, additional, Di Maio, Massimo, additional, Bossi, Paolo, additional, Falcone, Alfredo, additional, Citarella, Fabrizio, additional, Pantano, Francesco, additional, Ficorella, Corrado, additional, Filetti, Marco, additional, Adamo, Vincenzo, additional, Veltri, Enzo, additional, Pergolesi, Federica, additional, Occhipinti, Mario Alberto, additional, Nicolardi, Linda, additional, Tuzi, Alessandro, additional, Di Marino, Pietro, additional, Macrini, Serena, additional, Inno, Alessandro, additional, Ghidini, Michele, additional, Buti, Sebastiano, additional, Aprile, Giuseppe, additional, Lai, Eleonora, additional, Audisio, Marco, additional, Intagliata, Salvatore, additional, Marconcini, Riccardo, additional, Brocco, Davide, additional, Porzio, Giampiero, additional, Piras, Marta, additional, Rijavec, Erika, additional, Simionato, Francesca, additional, Natoli, Clara, additional, Tiseo, Marcello, additional, Vincenzi, Bruno, additional, Tonini, Giuseppe, additional, and Santini, Daniele, additional

Published
2021
Full Text
View/download PDF

24. Additional file 1 of PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Author

Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, and Cortellini, Alessio

Subjects
Data_FILES
Abstract

Additional file 1: Table S1

Published
2021
Full Text
View/download PDF

25. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Author

Cortellini, Alessio, primary, Cannita, Katia, additional, Tiseo, Marcello, additional, Cortinovis, Diego L., additional, Aerts, Joachim G.J.V., additional, Baldessari, Cinzia, additional, Giusti, Raffaele, additional, Ferrara, Miriam G., additional, D'Argento, Ettore, additional, Grossi, Francesco, additional, Guida, Annalisa, additional, Berardi, Rossana, additional, Morabito, Alessandro, additional, Genova, Carlo, additional, Antonuzzo, Lorenzo, additional, Mazzoni, Francesca, additional, De Toma, Alessandro, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Targato, Giada, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Gori, Stefania, additional, De Tursi, Michele, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Filetti, Marco, additional, Bracarda, Sergio, additional, Citarella, Fabrizio, additional, Russano, Marco, additional, Cantini, Luca, additional, Nigro, Olga, additional, Buti, Sebastiano, additional, Minuti, Gabriele, additional, Landi, Lorenza, additional, Ricciardi, Serena, additional, Migliorino, Maria R., additional, Natalizio, Salvatore, additional, Simona, Carnio, additional, De Filippis, Marco, additional, Metro, Giulio, additional, Adamo, Vincenzo, additional, Russo, Alessandro, additional, Spinelli, Gian P., additional, Di Maio, Massimo, additional, Banna, Giuseppe L., additional, Friedlaender, Alex, additional, Addeo, Alfredo, additional, Pinato, David J., additional, Ficorella, Corrado, additional, and Porzio, Giampiero, additional

Published
2021
Full Text
View/download PDF

26. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Author

Cortellini, Alessio, primary, Di Maio, Massimo, additional, Nigro, Olga, additional, Leonetti, Alessandro, additional, Cortinovis, Diego L, additional, Aerts, Joachim GJV, additional, Guaitoli, Giorgia, additional, Barbieri, Fausto, additional, Giusti, Raffaele, additional, Ferrara, Miriam G, additional, Bria, Emilio, additional, D'Argento, Ettore, additional, Grossi, Francesco, additional, Rijavec, Erika, additional, Guida, Annalisa, additional, Berardi, Rossana, additional, Torniai, Mariangela, additional, Sforza, Vincenzo, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Garassino, Marina Chiara, additional, De Toma, Alessandro, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Siringo, Marco, additional, Marchetti, Paolo, additional, Macerelli, Marianna, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Della Gravara, Luigi, additional, Inno, Alessandro, additional, Michele, De Tursi, additional, Grassadonia, Antonino, additional, Di Marino, Pietro, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Filetti, Marco, additional, Santini, Daniele, additional, Citarella, Fabrizio, additional, Russano, Marco, additional, Cantini, Luca, additional, Tuzi, Alessandro, additional, Bordi, Paola, additional, Minuti, Gabriele, additional, Landi, Lorenza, additional, Ricciardi, Serena, additional, Migliorino, Maria R, additional, Passiglia, Francesco, additional, Bironzo, Paolo, additional, Metro, Giulio, additional, Adamo, Vincenzo, additional, Russo, Alessandro, additional, Spinelli, Gian Paolo, additional, Banna, Giuseppe L, additional, Friedlaender, Alex, additional, Addeo, Alfredo, additional, Cannita, Katia, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, and Pinato, David J, additional

Published
2021
Full Text
View/download PDF

27. Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

Author

Cortellini, Alessio, primary, De Giglio, Andrea, additional, Cannita, Katia, additional, Cortinovis, Diego L., additional, Cornelissen, Robin, additional, Baldessari, Cinzia, additional, Giusti, Raffaele, additional, D'Argento, Ettore, additional, Grossi, Francesco, additional, Santoni, Matteo, additional, Catino, Annamaria, additional, Berardi, Rossana, additional, Sforza, Vincenzo, additional, Rossi, Giovanni, additional, Antonuzzo, Lorenzo, additional, Di Noia, Vincenzo, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Occhipinti, Mario Alberto, additional, Follador, Alessandro, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Gravara, Luigi Della, additional, Inno, Alessandro, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Filetti, Marco, additional, Montrone, Michele, additional, Citarella, Fabrizio, additional, Pensieri, Maria Vittoria, additional, Russano, Marco, additional, Cantini, Luca, additional, Nigro, Olga, additional, Leonetti, Alessandro, additional, Bordi, Paola, additional, Minuti, Gabriele, additional, Landi, Lorenza, additional, De Toma, Alessandro, additional, Donisi, Clelia, additional, Ricciardi, Serena, additional, Migliorino, Maria Rita, additional, Napoli, Valerio Maria, additional, Leone, Gianmarco, additional, Metro, Giulio, additional, Banna, Giuseppe L., additional, Friedlaender, Alex, additional, Addeo, Alfredo, additional, Ficorella, Corrado, additional, and Porzio, Giampiero, additional

Published
2021
Full Text
View/download PDF

28. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Author

Buti, Sebastiano, primary, Bersanelli, Melissa, additional, Perrone, Fabiana, additional, Tiseo, Marcello, additional, Tucci, Marco, additional, Adamo, Vincenzo, additional, Stucci, Luigia S., additional, Russo, Alessandro, additional, Tanda, Enrica T., additional, Spagnolo, Francesco, additional, Rastelli, Francesca, additional, Pergolesi, Federica, additional, Santini, Daniele, additional, Russano, Marco, additional, Anesi, Cecilia, additional, Giusti, Raffaele, additional, Filetti, Marco, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Gelibter, Alain, additional, Occhipinti, Mario Alberto, additional, Ferrari, Marco, additional, Vitale, Maria Giuseppa, additional, Nicolardi, Linda, additional, Chiari, Rita, additional, Rijavec, Erika, additional, Nigro, Olga, additional, Tuzi, Alessandro, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Conforti, Fabio, additional, Queirolo, Paola, additional, Bracarda, Sergio, additional, Macrini, Serena, additional, Gori, Stefania, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Di Cocco, Barbara, additional, Mallardo, Domenico, additional, Vitale, Maria Grazia, additional, Santoni, Matteo, additional, Patruno, Leonardo, additional, Porzio, Giampiero, additional, Ficorella, Corrado, additional, Pinato, David J., additional, Ascierto, Paolo A., additional, and Cortellini, Alessio, additional

Published
2021
Full Text
View/download PDF

29. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Author

Cortellini, Alessio, primary, Tucci, Marco, additional, Adamo, Vincenzo, additional, Stucci, Luigia Stefania, additional, Russo, Alessandro, additional, Tanda, Enrica Teresa, additional, Spagnolo, Francesco, additional, Rastelli, Francesca, additional, Bisonni, Renato, additional, Santini, Daniele, additional, Russano, Marco, additional, Anesi, Cecilia, additional, Giusti, Raffaele, additional, Filetti, Marco, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Gelibter, Alain, additional, Occhipinti, Mario Alberto, additional, Marconcini, Riccardo, additional, Vitale, Maria Giuseppa, additional, Nicolardi, Linda, additional, Chiari, Rita, additional, Bareggi, Claudia, additional, Nigro, Olga, additional, Tuzi, Alessandro, additional, De Tursi, Michele, additional, Petragnani, Nicola, additional, Pala, Laura, additional, Bracarda, Sergio, additional, Macrini, Serena, additional, Inno, Alessandro, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Di Cocco, Barbara, additional, Mallardo, Domenico, additional, Vitale, Maria Grazia, additional, Pinato, David James, additional, Porzio, Giampiero, additional, Ficorella, Corrado, additional, and Ascierto, Paolo Antonio, additional

Published
2020
Full Text
View/download PDF

30. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Author

Cortellini, Alessio, primary, Ricciuti, Biagio, additional, Tiseo, Marcello, additional, Bria, Emilio, additional, Banna, Giuseppe L, additional, Aerts, Joachim GJV, additional, Barbieri, Fausto, additional, Giusti, Raffaele, additional, Cortinovis, Diego L, additional, Migliorino, Maria R, additional, Catino, Annamaria, additional, Passiglia, Francesco, additional, Torniai, Mariangela, additional, Morabito, Alessandro, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Di Noia, Vincenzo, additional, Signorelli, Diego, additional, Gelibter, Alain, additional, Occhipinti, Mario Alberto, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Inno, Alessandro, additional, De Tursi, Michele, additional, Di Marino, Pietro, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Grossi, Francesco, additional, Filetti, Marco, additional, Pizzutilo, Pamela, additional, Russano, Marco, additional, Citarella, Fabrizio, additional, Cantini, Luca, additional, Targato, Giada, additional, Nigro, Olga, additional, Ferrara, Miriam G, additional, Buti, Sebastiano, additional, Scodes, Simona, additional, Landi, Lorenza, additional, Guaitoli, Giorgia, additional, Della Gravara, Luigi, additional, Tabbò, Fabrizio, additional, Ricciardi, Serena, additional, De Toma, Alessandro, additional, Friedlaender, Alex, additional, Petrelli, Fausto, additional, Addeo, Alfredo, additional, Porzio, Giampiero, additional, and Ficorella, Corrado, additional

Published
2020
Full Text
View/download PDF

31. A novel, pathogenic dinucleotide deletion in the mitochondrial MT-TY gene causing myasthenia-like features

Author

Lim, Albert Z., primary, McMacken, Grace, additional, Rastelli, Francesca, additional, Oláhová, Monika, additional, Baty, Karen, additional, Hopton, Sila, additional, Falkous, Gavin, additional, Töpf, Ana, additional, Lochmüller, Hanns, additional, Marini-Bettolo, Chiara, additional, McFarland, Robert, additional, and Taylor, Robert W., additional

Published
2020
Full Text
View/download PDF

32. Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Author

Cortellini, Alessio, primary, Tiseo, Marcello, additional, Banna, Giuseppe L, additional, Cappuzzo, Federico, additional, Aerts, Joachim GJV, additional, Barbieri, Fausto, additional, Giusti, Raffaele, additional, Bria, Emilio, additional, Cortinovis, Diego, additional, Grossi, Francesco, additional, Migliorino, Maria R, additional, Galetta, Domenico, additional, Passiglia, Francesco, additional, Santini, Daniele, additional, Berardi, Rossana, additional, Morabito, Alessandro, additional, Genova, Carlo, additional, Mazzoni, Francesca, additional, Noia, Vincenzo Di, additional, Signorelli, Diego, additional, Tuzi, Alessandro, additional, Gelibter, Alain, additional, Marchetti, Paolo, additional, Macerelli, Marianna, additional, Rastelli, Francesca, additional, Chiari, Rita, additional, Rocco, Danilo, additional, Gori, Stefania, additional, De Tursi, Michele, additional, Mansueto, Giovanni, additional, Zoratto, Federica, additional, Santoni, Matteo, additional, Tudini, Marianna, additional, Rijavec, Erika, additional, Filetti, Marco, additional, Catino, Annamaria, additional, Pizzutilo, Pamela, additional, Sala, Luca, additional, Citarella, Fabrizio, additional, Marco, Russano, additional, Torniai, Mariangela, additional, Cantini, Luca, additional, Targato, Giada, additional, Sforza, Vincenzo, additional, Nigro, Olga, additional, Ferrara, Miriam G, additional, D’Argento, Ettore, additional, Buti, Sebastiano, additional, Bordi, Paola, additional, Antonuzzo, Lorenzo, additional, Scodes, Simona, additional, Landi, Lorenza, additional, Guaitoli, Giorgia, additional, Baldessari, Cinzia, additional, Gravara, Luigi Della, additional, Dal Bello, Maria Giovanna, additional, Belderbos, Robert A., additional, Bironzo, Paolo, additional, Carnio, Simona, additional, Ricciardi, Serena, additional, Grieco, Alessio, additional, De Toma, Alessandro, additional, Proto, Claudia, additional, Friedlaender, Alex, additional, Cantale, Ornella, additional, Ricciuti, Biagio, additional, Addeo, Alfredo, additional, Metro, Giulio, additional, Ficorella, Corrado, additional, and Porzio, Giampiero, additional

Published
2020
Full Text
View/download PDF

33. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Author

Cortellini, Alessio, primary, Bersanelli, Melissa, additional, Santini, Daniele, additional, Buti, Sebastiano, additional, Tiseo, Marcello, additional, Cannita, Katia, additional, Perrone, Fabiana, additional, Giusti, Raffaele, additional, De Tursi, Michele, additional, Zoratto, Federica, additional, Marconcini, Riccardo, additional, Russano, Marco, additional, Zeppola, Tea, additional, Anesi, Cecilia, additional, Filetti, Marco, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Gelibter, Alain, additional, De Galitiis, Federica, additional, Vitale, Maria Giuseppa, additional, Rastelli, Francesca, additional, Tudini, Marianna, additional, Silva, Rosa Rita, additional, Atzori, Francesco, additional, Chiari, Rita, additional, Ricciuti, Biagio, additional, De Giglio, Andrea, additional, Migliorino, Maria Rita, additional, Mallardo, Domenico, additional, Vanella, Vito, additional, Mosillo, Claudia, additional, Bracarda, Sergio, additional, Rinaldi, Silvia, additional, Berardi, Rossana, additional, Natoli, Clara, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, and Ascierto, Paolo A., additional

Published
2020
Full Text
View/download PDF

34. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

Author

Cortellini, Alessio, primary, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Giusti, Raffaele, additional, Perrone, Fabiana, additional, Di Marino, Pietro, additional, Tinari, Nicola, additional, De Tursi, Michele, additional, Grassadonia, Antonino, additional, Cannita, Katia, additional, Tessitore, Alessandra, additional, Zoratto, Federica, additional, Veltri, Enzo, additional, Malorgio, Francesco, additional, Russano, Marco, additional, Anesi, Cecilia, additional, Zeppola, Tea, additional, Filetti, Marco, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Cappellini, Gian Carlo Antonini, additional, De Galitiis, Federica, additional, Vitale, Maria Giuseppa, additional, Rastelli, Francesca, additional, Pergolesi, Federica, additional, Berardi, Rossana, additional, Rinaldi, Silvia, additional, Tudini, Marianna, additional, Silva, Rosa Rita, additional, Pireddu, Annagrazia, additional, Atzori, Francesco, additional, Iacono, Daniela, additional, Migliorino, Maria Rita, additional, Gelibter, Alain, additional, Occhipinti, Mario Alberto, additional, Martella, Francesco, additional, Inno, Alessandro, additional, Gori, Stefania, additional, Bracarda, Sergio, additional, Zannori, Cristina, additional, Mosillo, Claudia, additional, Parisi, Alessandro, additional, Porzio, Giampiero, additional, Mallardo, Domenico, additional, Fargnoli, Maria Concetta, additional, Tiseo, Marcello, additional, Santini, Daniele, additional, Ascierto, Paolo A, additional, and Ficorella, Corrado, additional

Published
2020
Full Text
View/download PDF

35. Additional file 3: of A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Author

Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Marino, Pietro Di, Tinari, Nicola, Tursi, Michele De, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Cappellini, Gian Antonini, Galitiis, Federica De, Vitale, Maria, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa, Annagrazia Pireddu, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, Giglio, Andrea De, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria, Ascierto, Paolo, Ficorella, Corrado, and Natoli, Clara

Subjects
genetic structures
Abstract

Univariate and multivariate analyses with logistic regression of Objective Response Rate. (DOC 49 kb)

Published
2019
Full Text
View/download PDF

36. Additional file 1: of A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Author

Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Marino, Pietro Di, Tinari, Nicola, Tursi, Michele De, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Cappellini, Gian Antonini, Galitiis, Federica De, Vitale, Maria, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa, Annagrazia Pireddu, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, Giglio, Andrea De, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria, Ascierto, Paolo, Ficorella, Corrado, and Natoli, Clara

Abstract

List of oncological institutions of the study. (DOCX 15 kb)

Published
2019
Full Text
View/download PDF

37. Additional file 2: of A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Author

Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Marino, Pietro Di, Tinari, Nicola, Tursi, Michele De, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Cappellini, Gian Antonini, Galitiis, Federica De, Vitale, Maria, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa, Annagrazia Pireddu, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, Giglio, Andrea De, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria, Ascierto, Paolo, Ficorella, Corrado, and Natoli, Clara

Subjects
animal diseases, bacteria, chemical and pharmacologic phenomena, biochemical phenomena, metabolism, and nutrition
Abstract

Immune-related adverse events of any grade and G3/G4 immune-related adverse events. (DOCX 15 kb)

Published
2019
Full Text
View/download PDF

39. Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.

Author

Cortellini, Alessio, primary, Buti, Sebastiano, additional, Santini, Daniele, additional, Giusti, Raffaele, additional, Tiseo, Marcello, additional, Zoratto, Federica, additional, Marchetti, Paolo, additional, Bersanelli, Melissa, additional, De Galitiis, Federica, additional, Vitale, Maria Giuseppa, additional, Rastelli, Francesca, additional, Berardi, Rossana, additional, Tudini, Marianna, additional, Atzori, Francesco, additional, Iacono, Daniela, additional, Inno, Alessandro, additional, Bracarda, Sergio, additional, Natoli, Clara, additional, Ascierto, Paolo Antonio, additional, and Ficorella, Corrado, additional

Published
2019
Full Text
View/download PDF

40. Spatial consistency and bias in avalanche forecasts – a case study in the European Alps

Author

Techel, Frank; https://orcid.org/0000-0001-5686-6127, Mitterer, Christoph, Ceaglio, Elisabetta, Coléou, Cécile, Morin, Samuel; https://orcid.org/0000-0002-1781-687X, Rastelli, Francesca, Purves, Ross S, Techel, Frank; https://orcid.org/0000-0001-5686-6127, Mitterer, Christoph, Ceaglio, Elisabetta, Coléou, Cécile, Morin, Samuel; https://orcid.org/0000-0002-1781-687X, Rastelli, Francesca, and Purves, Ross S

Abstract

In the European Alps, the public is provided with regional avalanche forecasts, issued by about 30 forecast centers throughout the winter, covering a spatially contiguous area. A key element in these forecasts is the communication of avalanche danger according to the five-level, ordinal European Avalanche Danger Scale (EADS). Consistency in the application of the avalanche danger levels by the individual forecast centers is essential to avoid misunderstandings or misinterpretations by users, particularly those utilizing bulletins issued by different forecast centers. As the quality of avalanche forecasts is difficult to verify, due to the categorical nature of the EADS, we investigated forecast goodness by focusing on spatial consistency and bias, exploring real forecast danger levels from four winter seasons (477 forecast days). We describe the operational constraints associated with the production and communication of the avalanche bulletins, and we propose a methodology to quantitatively explore spatial consistency and bias. We note that the forecast danger level agreed significantly less often when compared across national and forecast center boundaries (about 60%). Furthermore, several forecast centers showed significant systematic differences in terms of more frequently using lower (or higher) danger levels than their neighbors. Discrepancies seemed to be greatest when analyzing the proportion of forecasts with danger level 4 – high and 5 – very high. The size of the warning regions, the smallest geographically clearly specified areas underlying the forecast products, differed considerably between forecast centers. Region size also had a significant impact on all summary statistics and is a key parameter influencing the issued danger level, but it also limits the communication of spatial variations in the danger level. Operat

Published
2018

41. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Author

Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco, Rastelli, Francesca, Sobrero, Alberto, Turci, Daniele, Sternberg, Cora N., Porta, Camillo, Cappuzzo, Federico, Tortora, Giampaolo, Tassinari, Davide, Panni, Stefano, Pazzola, Antonio, and Surico, Gianmarco

Subjects
DRUG side effects, RENAL cell carcinoma, NIVOLUMAB, TERMINATION of treatment, RENAL cancer
Abstract

Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Methods: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model. Results: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7-6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3-4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0. 003) and multivariable (HR 0.57, p = 0.02) analysis. Conclusions: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. P1.06-006 Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP)

Author

Cappuzzo, Frederico, primary, Delmonte, Angelo, additional, Capici, Serena, additional, Crinò, Lucio, additional, Logroscino, Antonio Fabio, additional, Sandri, Paolo, additional, Livi, Lorenzo, additional, Vitiello, Fabiana, additional, Signorelli, Diego, additional, Calabrò, Luana, additional, Turci, Daniele, additional, Quadrini, Silvia, additional, Antonelli, Paola, additional, Giusti, Sabrina, additional, Di Costanzo, Francesco, additional, Rastelli, Francesca, additional, Marchetti, Paolo, additional, Finocchiaro, Giovanna, additional, Cortesi, Enrico, additional, and Ardizzoni, Andrea, additional

Published
2017
Full Text
View/download PDF

44. P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)

Author

Grossi, Francesco, primary, Crinò, Lucio, additional, Catino, Annamaria, additional, Canova, Stefania, additional, Delmonte, Angelo, additional, Ardizzoni, Andrea, additional, Garassino, Marina, additional, Scagnoli, Simone, additional, Cappuzzo, Frederico, additional, Turci, Daniele, additional, Quadrini, Silvia, additional, Antonelli, Paola, additional, Marchetti, Paolo, additional, Santoro, Armando, additional, Giusti, Sabrina, additional, Di Costanzo, Francesco, additional, Rastelli, Francesca, additional, Sandri, Paolo, additional, Livi, Lorenzo, additional, and De Marinis, Filippo, additional

Published
2017
Full Text
View/download PDF

45. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme.

Author

De Giorgi, Ugo, Cartenì, Giacomo, Giannarelli, Diana, Basso, Umberto, Galli, Luca, Cortesi, Enrico, Caserta, Claudia, Pignata, Sandro, Sabbatini, Roberto, Bearz, Alessandra, Buti, Sebastiano, Lo Re, Giovanni, Berruti, Alfredo, Bracarda, Sergio, Cognetti, Francesco, Rastelli, Francesca, Fornarini, Giuseppe, Porta, Camillo, Turci, Daniele, and Sternberg, Cora N.

Subjects
DRUG efficacy, ANTINEOPLASTIC agents, RENAL cell carcinoma, CANCER patients, PATIENT acceptance of health care
Abstract

Objective: To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods: Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. Patients included in the analysis had received ≥1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Results: A total of 389 patients were enrolled between July 2015 and April 2016, of whom 18% were aged ≥75 years, 6.7% had non‐clear cell RCC, 49.6% had bone and 8.2% brain metastases, and 79% had received ≥2 previous lines of therapy. The most common any‐grade treatment‐related AEs were fatigue (13%) and rash (9%). Twenty‐two patients (5.7%) discontinued treatment because of AEs. There were no treatment‐related deaths. The objective response rate was 23.1%. At a median follow‐up of 12 months, the median progression‐free survival was 4.5 months (95% confidence interval 3.7–6.2) and the 12‐month overall survival rate was 63%. Similar survival rates were reported among patients with non‐clear‐cell histology, elderly patients, those with bone and/or brain metastases, and those who had received prior first‐line sunitinib or pazopanib, or prior everolimus. Conclusion: The safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non‐clear‐cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Medical oncologist’s commitment in the end of life (EoL) care of cancer patients: The caregiver's perspective.

Author

Bascioni, Romeo, primary, Giorgi, Francesca, additional, Esperide, Barbara, additional, Basirat, Farnoosh, additional, Borriello, Maria Rosaria, additional, Brugni, Manuela, additional, Scriboni, Sonia, additional, Rastelli, Francesca, additional, Appignanesi, Remo, additional, Picciotti, Giovanna, additional, De Signoribus, Giorgio, additional, and Giustini, Lucio, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results